‹ ›
MYP_012039
← PREVIOUS NEXT → BACK
Basic Information
DP-107
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-Pneumovirus ▸ Anti-RSV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Venom / Toxin ▸ General toxin ▸ Toxic
Standard
38 amino acids
C202H336N60O55
Standard
Sequence
NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ
Physicochemical Analysis
4485.20 Da
9.69
1.85
1.59
0.0487
-0.18
0.49
-0.03
48.47
138.68
0.0526
6990.00
6990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1919.31
-14.52
65.0
58.0
156.0
317.0
4.0
45.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0300998 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 HR1 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibitor
HIV
PaperA molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion; Patent: Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides PMID7538176 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/7538176/ PatentUS 7556813 B2
RECORD: Rec_0316475 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
Qualitative inhibition
PaperHighly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors PatentUS7919101
RECORD: Rec_0353022 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
Evidence URLhttps://patents.google.com/patent/US20040091855A1/en PatentUS 2004/0091855 A1
RECORD: Rec_0370097 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 HR1 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV
HIV
PaperA molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion; Patent: Method for production of antivirals by use of HIV-derived HR1 peptides, and trimers formed therefrom PMID7538176 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/7538176/ PatentUS 20040091855
RECORD: Rec_0374208 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV gp41 HR1 fusion inhibitor
32630.0
Structure & Mods
synthetic linear peptide [Linear]
mixed L/D amino-acid peptide [Mixed]
Bio-Activity Profile
Antiviral Anti-HIV Anti-RSV Fusion inhibitor
HIV
PaperA molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion; Patent: Human respiratory syncytial virus peptides with antifusogenic and antiviral activities PMID7538176 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/7538176/ PatentUS 6228983 B1
FIRST PREV 1 2
Showing 5 records on this page · Page 2 of 2